Presenting Companies

Spring 2021 Conference

(as of March 25, 2021)


Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for our ARC’s is targeted conditioning, which is intended to selectively kill patient’s cancer cells and certain immune cells prior to potentially curative BMT or Bone Marrow Transplant, CAR-T and other cell therapies and gene therapies. Actinium is also developing ARCs in combination with other therapeutic modalities to capitalize the known synergistic potential of radiation.


Adanate is focused on developing novel mechanisms that can enhance both adaptive and innate immunity. The company has identified novel mechanisms involved in cell types, including T-cells, NK cells, dendritic cells, macrophages and myeloid derived suppressor cells that provide new approaches to enhance immunity. Modulating key pathways by which T-cells, macrophages and NK cells kill tumor cells may lead to new immuno-therapeutics capable of improving patient’s quality of life. Adanate believes that this coordinated approach to enhance both adaptive and innate immunity will be useful in creating novel therapeutics to treat multiple oncology indications and other immune related disorders.

AHEAD Medicine focuses on developing AI-based cancer diagnostics tools to reduce treatment delay caused by analysis bottleneck. Our lead product is AHEAD-flow platform, a machine learning based, fully automated analysis tool for clinical cytometry exams on blood cancer patients that is 100 times faster than current method. When implemented, we project to reduce up to 80% of idle time for abnormal cases to be identified.


Founded in 2020 and headquartered in San Diego, California, Alyra Therapeutics is focused on ALY101, a PAK1 inhibitor which blocks the interaction between PAK1 and its activator, RHOJ, preventing the activation of PAK1 and suppressing tumor initiation, growth and metastasis in models of melanoma and other cancers. Published data from Genentech researchers and other groups demonstrates PAK1 inhibition strongly synergizes with multiple targeted therapies and checkpoint inhibitors, with PAK1-expressing cancers comprising a $3.1 B TAM in oncology indications alone. We see huge potential in adjunctive use of ALY101 in combination with existing targeted therapies and immuno-oncology drugs to improve drug safety and efficacy via this drug sparing effect. The Alyra team has decades of oncology drug development experience from companies including Genentech/Roche, Pfizer, Chugai, and Schrödinger and multiple venture backed companies. We are raising a $5 M convertible note to finance filing of the ALY101 IND in Q2 2022.


Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company based in South San Francisco, CA that is developing a novel platform of dual-action biologics to selectively relieve immune suppression and drive T-cell activation/polarization, to restore anti-cancer immunity in patients. The company’s lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy. In parallel, it drives improved T cell effector function. AMV564 has exhibited an excellent clinical safety profile and combinability with checkpoint inhibition and represents a unique opportunity to bring new treatment options to cancer patients under-served by immunotherapy.


Apricity’s technology platform is designed to empower The Oncology Teams with Real-Time Data and Expert Knowledge to Better Manage Cancer Patients on Therapy. Bridging the gaps by fusing expert care for patients with expert resources for healthcare professionals, Apricity is changing the paradigm of care for all people living with cancer.


Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers and CHB. The Company is dedicated to developing and bringing to market therapies that target each class of molecular pathways regulating programmed cell death. Headquartered in Suzhou, China, we are a rapidly growing company with US Headquarters in Rockville MD. Ascentage Pharma is listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.


Avidea Technologies, Inc. (Baltimore, MD) is developing safer and more effective immunotherapies for treating cancer and autoimmune diseases enabled by two polymer-drug conjugate technologies, SNAPvaxTM and SyntholyticTM. SNAPvax is the most efficient vaccine platform for inducing T cell immunity reported to date (Lynn et al. Nature Biotechnology 2020) and can be repeatedly administered by the intravenous (IV) route to maximize efficacy. Two SNAPvax candidates, a vaccine for treating HPV+ cancers and a tolerance vaccine for inducing targeted (less toxic, potentially curative) immune suppression for treating multiple sclerosis are both entering clinic in 2022. As an orthogonal approach to cancer treatment, Avidea’s Syntholytic uses dual responsiveness to selectively target and release immunostimulants in tumors to maximize tumor killing while mitigating systemic toxicity. Syntholytic-TLR-7/8a for treating advanced cancers will advance to clinical testing in 2023. With established GMP manufacturing processes and demonstrated safety and efficacy in primates, SNAPvax and Syntholytic enabled candidates have a clear path to the clinic.


The BioEclipse Therapeutic platform is comprised of innate and adaptive immune cells poised during manufacturing to find and kill cancer cells, and then combined with a replicating oncolytic virus to increase tumor killing potential. The BioEclipse treatment strategy uses a multi-mechanistic therapeutic with billions of high potency therapeutic effectors that kill targeted tumor cells. This reduces the likelihood of tumor resistance to therapy.


Cogen Bioscience is a late pre-clinical stage biotechnology company developing innovative cancer targeting molecules for diagnostic and therapeutic applications. Cogen’s technology is built around a platform of highly engineered antibody fragments that are optimized for safety, stability, and pharmacokinetics to match precisely to the intended use. Cogen’s lead products are for the precision diagnosis of a broad range of solid tumors. Cogen is also developing radiotherapeutic agents from its platform.


Creatv MicroTech is a privately-held company which specializes in microfabrication and biodetection. The company’s business is based on cutting-edge research and development – leveraging our expertise in the sciences and engineering related to high-aspect-ratio microfabrication and ultra-sensitive biodetection. Creatv’s fabrication of micro-metal and composite microstructures is unmatched by anyone in the world. Creatv’s microfabricated CellSieveTM microfilters are ideally suited for liquid cell biopsy for cancer diagnostics.


Cumberland Emerging Technologies based in Nashville, TN offers services tailored to inventor scientists seeking a corporate partner to assist in developing their biomedical technologies. We licensed a novel radiosensitizer small molecule therapeutic discovered by our partners at Vanderbilt University named YTR107. In preclinical studies, YTR107 augments radiation-induced lethality by inhibiting nucleophosmin1, a protein required to repair radiation-induced DNA damage. This therapeutic has tremendous potential to significantly improve chemoradiation efficacy in solid tumor cancers, especially non-small cell lung cancer, without increasing toxicity as part of new promising combination treatment regimens that can include immunotherapies. We are seeking partners and/or investors to bring this and other oncological early stage technologies to market in our pipeline.

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, GP1681 is positioned to become a new best practice in medicine.


Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies. Cytocom has developed a multi-receptor targeting system developing analogs of noroxymorphone and proenkephalin to address numerous therapeutic areas including autoimmune, anti-inflammatory, anti-viral and cancers. Cytocom has expanded its understanding of the relationship between noroxymorphone and proenkephalin analogs determining how multiple factors impact pharmacokinetic – pharmacodynamic relationships, potency, and selectivity.


Deep Lens is an AI company focused on deploying it's award-winning VIPER platform to cancer centers free of charge so that they can more effectively match cancer patients to life saving clinical trials, while working with biopharma clients to help compress trial timelines and help get life saving therapies to market faster by providing them better insights and higher patient/trial enrollment. The company has raised over $20M from angel investors, industry veterans and venture capital firms including Northpond Ventures, Sierra Ventures (Silicon Valley), Rev1 Ventures and Tamarind Hill Fund. Deep Lens is based in Columbus, Ohio and is targeting 2021 for its Series B round.

EarlyDx is a seed-stage company focusing on early diagnosis of cancer. Our CancerRadar Test is a blood-based test incorporating both proprietary assay technology and machine leaning algorithm. The assay technology cost-effectively builds a sequencing library from informative circulating cell-free DNA. An ensemble machine learning classifier combines multiple epi-genomic and genomic features obtained from our assay to not only detect cancer at early stages but also locate its tissue of origin.


Ehmet health is positioned to be the leader within the radiotherapy market dedicated to improving outcomes and be the gold-standard treatment for treating breast cancer, the most diagnosed cancer amongst women. Ehmet health will achieve this by delivering clinical solutions that are cost-effective, clinically superior and easy to operate. The “MammoKnife” is the culmination of over a decade of work and is a radiation therapy device designed specifically for the breast. The design isolate’s the breast from all other organs avoiding unnecessary radiation and dramatically reducing secondary toxicity. The proprietary shielding allows the disruptive technology to be deployed without the need for traditional radiation bunkers meaning, any surgery center, outpatient clinic or mobile providers will be potential partners and customers. Reimbursement is in place to address the financial needs of our customers and shareholders and will take into account all current and future reimbursement practices. Following successful commercialization of the breast radiotherapy device, we intend to apply our platform technology to develop other self-shielded devices for general purpose radiotherapy.


Elpis Biopharmaceuticals is developing multifunctional immunotherapies, including dual-targeted armored CAR-T cells and bispecific biologics, aimed at activating the immune system to overcome tumor resistance. Through its proprietary antibody discovery and protein engineering platforms, Elpis is advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers. Elpis is headquartered in Lexington, MA, with research labs in the U.S. and China.


ENB Therapeutics is a privately held clinical stage company developing first in class ETBR inhibitors to overcome resistance to the immune checkpoint inhibitors. Our Phase 1/2 trials are being conducted starting March 2020 in collaboration with Merck to assess safety and efficacy of our lead product ENB-003 in combination with pembrolizumab. We are raising a $25M Series B financing to support of Ph2 trials and anticipate achieving clinical proof of concept within the year.

Filtricine, Inc. is a clinical stage biotechnology company founded on the basis of a nutrient modulation platform for identifying metabolic vulnerabilities in cancer and other diseases. Our technology termed Targeted Nutrients Deprivation (TND) is a method to deplete from the bloodstream nutrients specifically required by cancer cells but not by normal cells. Our first product is a food product – a suite of complete replacement meals that lack several cancer-promoting nutrients. Filtricine has started its first clinical trial of the TND diet in prostate cancer patients at Stanford University Medical Center.


FSD Pharma, Inc. is a publicly traded holding company, since May 2018. FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201 ultra-micronized palmitoylethanolamide (PEA). Ultra-Micro PEA stabilizes mast cells and down-regulates the pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of the endocannabinoid system of the human body.

Geneius is a 4th generation T cell company for the treatment of hematological and solid tumors. Geneius’ autologous T cell products are designed to be administered first-line, as outpatient therapy by the local community oncologist ready when the patient needs to be treated via two 30 minute infusions. The company’s T cell products solve the challenges associated with CAR T and allogeneic CAR T in lymphoma and TILs in lung cancer and other solid tumors. In addition to the best T cells in the business and a robust low-cost closed system manufacturing T cell manufacturing platform, Geneius has a strong IP position, and the management and the scientific team experienced in leading T cell companies.


Commercial Stage RNA Platform for the Next Generation Cures - Cancer and Infectious Diseases. OneRNA® enables the design of mRNA vaccines as well as sophisticated combinatorial clinical studies. Currently, OneRNA® has been CLIA certified in women’s cancer and COVID-19 using FFPE, blood, and saliva samples. The OneRNA® platform enables a paradigm shift from ONE disease, ONE marker, and ONE drug to ONE patient, MANY markers, and MULTIPLE treatment options that go beyond drugs. Based on our data in multiple cancers, we envision that by testing and treating accordingly, we can prolong the life of most patients.


Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

Heidelberg Pharma is a publicly listed, biopharmaceutical company focused on oncology. It is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary and innovative technology platform is being applied to develop the Company’s own therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates also for other indication fields. The proprietary lead candidate HDP-101, a BCMA ATAC for multiple myeloma, recently received IND clearance by the FDA for a Phase I/IIa study, which is set to start in Q2.


Illumacell Inc. a company focused on Beating Cancer with Light. The patented technology uses high power Red LEDs to photoactivate a photosensitive drug to kill tumor cells deep inside a person’s body.  The Illumacell breakthrough technology has the potential to deliver light far deeper into body tissues without the need for surgery or other invasive approaches.  Proof-of-concept studies have demonstrated light penetration of up to 4 cm in simulated breast tissue and up to 7 cm in muscle. This advance opens the possibility of treating a wide range of cancers. Illumacell light devices have been shown to inhibit growth and even eliminate cancer in mice.


Imagion Biosystems is developing a new, non-radioactive and safe diagnostic imaging technology utilising its proprietary MagSenseTM technology. Combining biotechnology and nanotechnology, Imagion Biosystems aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. MagSenseTM technology is the first imaging technology to use targeted magnetic nanoparticles to tag and detect cancers. The tiny bio-safe particles act as a magnetic beacon detectable when they attach to cancer cells. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.


Our company partners with international physicians to help develop/expand delivery of novel and existing cancer therapy modalities to dramatically improve cancer outcomes. These approaches expand on traditional surgery, radiation and chemotherapy to include hyperthermia. We provide resources and referrals to patients for comprehensive state of the art multimodality cancer therapies leveraging optimizing safe and effective delivery of Whole-Body Hyperthermia (WBH).


Immunicom combines advancement in molecule development with a unique therapeutic delivery approach, providing safe and effective solutions for critical conditions such as cancer, auto-immune diseases, renal, and inflammatory diseases. We inhibit disease growth without using drugs and associated toxic side effects by targeted removal of cytokines and other soluble factors that suppress a natural immune response. Our first area of focus is oncology and Immunicom has received initial approval in Europe for advance refractory Triple Negative Breast Cancer (TNBC) through a CE Mark and has been classified by the FDA as a Breakthrough Technology. We are working toward a soft commercial launch in various European countries, along with Israel and Turkey, by Q4 2021. We expect initial FDA approval by late 2022, early 2023. We have raised $32M to-date from high net-worth individuals and family offices through Series A and Series B rounds of funding. We are currently raising $23M in a Bridge round, $8M of which has already been secured through our existing investor base.


Impact Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. Impact pipeline products include PARP inhibitor(Senaparib/ IMP4297), Wee1 inhibitor(IMP7068), and other novel DDR agents inhibitors.


Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology.

Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a non-canonical, WNT-signaling protein (SFRP2) that is highly expressed in multiple hematological and solid cancers.  SFRP2 is secreted by tumor cells, endothelial cells, and activated T-cells, and plays a direct role in a series of cellular processes including angiogenesis, cell survival, cell migration and metastasis, and production of T-cell exhaustion markers. Innova’s lead humanized mAb is IVT-8086 and has been shown to inhibit tumor progression and metastases in multiple tumor types.   Innova’s mAb therapy is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, breast cancer and pancreatic cancer.   The opportunity for this anticancer therapy as a monotherapy and in combination with other chemotherapy agents will be expanded across other solid tumors.


Jubilant Therapeutics Inc., US headquartered patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations.

Katena Oncology is a NYC-based biopharma company, developing first-in-class immunotherapies with companion diagnostics for patients who do not respond to standard of care therapies. We have a team of oncology experts from Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine, and pharma executives who have developed blockbuster therapies. Katena's proprietary platform captures cancer biology ex-vivo with unprecedented accuracy, unlocking highly specific targets and a new class of cancer biologics. Katena Oncology has recently won the Bristol-Myers Squibb Golden Ticket Award in New York City.


Kineta is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in innate immunity to advance a focused pipeline of novel immunotherapies in oncology and neuroscience. Kineta’s lead immuno-oncology program is KVA12.1, a potential “best-in-class” anti-VISTA mAb to reprogram the Tumor Microenvironment (TME) in preclinical development. VISTA is a differentiated mechanism that blocks suppressive cells, enhances immune cell activation in cold tumors and can complement checkpoint inhibitor therapy. KCP506 is a novel non-opioid, a first-in-class α9α10 nAChR antagonist, in Phase 1 clinical development for chronic neuropathic pain that is partnered with Genentech (Roche) in a $359M strategic partnership.

LeadInvent Pharma (LIP) is a US HQ nanotechnology company. The company is managed by a team of pharma and drug discovery veterans bringing over 350 man-year experience in drug development. LIP team has developed a unique patented medical-grade gel named GBGel which would allow surgeons to remove brain cancer tissue that they are not able to remove using conventional surgical methods.

LB Logo Square Text bottom.png

LifeBridge’s wearable therapeutic device can extend the proven benefits of Tumor Treating Fields (TTF) therapy to the underserved market of patients with metastatic cancer. Our Mission is to transform metastatic cancer from a terminal prognosis to a manageable disease like diabetes using our patented Adaptive Tumor Treating Field (ATTF) technology.


Lightpoint Medical is a technology leader in precision-guided robotic cancer surgery. We are developing miniaturized imaging and sensing tools for advanced intra-operative cancer detection. Our mission is to improve the lives of people with cancer by transforming the efficacy of robotic surgery.


MAIA Biotech is a targeted therapy, immuno-oncology company that develops drug candidates targeting cancers with high unmet patient needs through Phases 1-2 and plans to collaborate with partners for further development and commercialization. Lead drug candidates with novel mechanism of action and strong preclinical results that demonstrated curative effects with cancer-specific immunologic memory that prevents cancer from recurrence. Recently entered into collaboration with Regeneron to commence Ph 1/2 in Non-Small Cell Lung Cancer. Initial focus on Non-Small Cell Lung Cancer and Colorectal cancer with significant potential from label expansions across multiple major tumor types: Hepatocellular, Melanoma, Breast, Neuroblastoma and Brain Cancers.


Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented small molecule drugs that destroy SARS-CoV-2, the COVID virus, and other viruses. This world-first drug class called Maxwell’s PeptoidsTM mimics natural human immune system antimicrobial peptides.  Maxwell Biosciences recently announced confirmation by US Govt-funded labs that Maxwell's lead drug candidate has direct virucidal action against Herpes virus and SARS-CoV-2, the COVID-19 virus. Additionally, recent live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” virucidal drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics. Maxwell is raising funds for advanced preclinical and human trials.


NaNotics, LLC is an U.S. biotechnology company headquartered in Marin, California. NaNotics is developing a novel method of treating disease via injectable nanoparticles called NaNots, which deplete specific molecules from blood that drive or enable diseases including cancer, sepsis, Alzheimer’s Disease and aging. NaNots are not drugs or drug delivery systems. In fact, NaNots are really the opposite of drugs, which all add molecules to the body. NaNots, in contrast, are engineered to deplete from blood specific pathogenic molecular targets. You can think of NaNots as the world’s smallest, most specific, non-toxic sponges. NaNots are injected I.V. and cleared naturally by macrophage phagocytosis.


NanoView Biosciences enables life science researchers to better understand the biological role of exosomes and viral vectors and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The company’s proprietary product, the ExoView® platform, is designed to specifically detect and fully characterize exosomes and viral vectors for use in basic and translational research, enabling the development of diagnostic and therapeutic products for nanomedicine.

Novian Health has developed a proprietary laser therapy system for focal destruction of tumors. The first product, Novilase® Breast Therapy, is a minimally invasive alternative to lumpectomy using ultrasound image guidance under local anesthetic. Novilase has shown improved efficacy at a lower cost versus surgery. Patients benefit from a quicker recovery (hours not days), no need for cosmetic reconstruction, and improved health-related quality of life outcomes. An immunotherapeutic benefit may also accrue to patients as a result of the thermal ablation.


Nuview Life Sciences Inc. is a clinical-stage oncology company that is developing a cancer diagnostic test and treatment delivery system that could reduce the need for costly, less accurate tests and surgical biopsies. The binary – yes/no – test employs a proprietary peptide construct, NV-VPAC1, that targets a specific receptor, called vasoactive intestinal peptide receptor type 1 (VPAC1), that is overexpressed on the surface of cancer cells.

ODS Medical Inc. is a Montreal-based medical technology company dedicated to bringing the next generation of diagnostic tools to the hands of physicians by bringing together the power of machine learning and molecular imaging to develop optical biopsy tools based on Raman spectroscopy. The SentryTM system for real-time tissue characterization detects the presence of invasive cancer directly in patients, pushing the limits of cancer detection in many procedures. By integrating cutting edge optical probes with sophisticated AI software, ODS Medical empowers doctors to make critical decisions, in real-time, to improve patient safety and outcomes.


OncoLize: “Treating Tumors from the Inside” 1. OncoLize (Leiden – NL) develops injectable drug depots for localized, intra-tumoral injections and is in its final approach to IND and CT Phase I/II for pancreatic cancer and other indications. 2. Delivering generic chemo or new assets in this manner offers precision: 10-100x higher concentration at target with much smaller doses and up to 1000x lower drug levels outside the tumor… 3. As 90% of all cancers are solid tumors and 70% of all tumors are diagnosed before later stage metastasis, this is a powerful proposition to treat patients with better outcome, far less side effects and making it Triple A: Affordable and Accessible for All. 4. OncoLize is raising a Series A in two steps of US$ 4.2mln and 6mln to achieve CT phase I/II studies in up to 3 indications and is specifically looking for impact investors that share our mission. OncoLize (2020 – Leiden, NL) develops injectable drug depots to release generic chemo or other compounds inside solid tumors: improved efficacy; no/low side-effects; affordable. The first prototype has proven effective in NSCLC and pancreatic tumor models and will be made applicable to other types of tumors. A highly experienced and passionate management team is raising US$ 10 mln to take the products to initial clinical trials in selected tumor diseases; impact investors most welcome to share our mission..


Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova is committed to delivering novel solutions to cancer patients in need, seeking to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.


OncoTartis is exploring a proprietary drug discovery approach called “TARTIS” (TARTIS = TARgeting TISsue). TARTIS is designed to develop small molecules for treatment of malignancies originating from specific tissues that are either non-essential for the general viability of mammalian organism (i.e., gender-associated tissues or melanocytes) or can be effectively replaced (hematopoietic system).  OncoTartis lead candidate is OT-82, aAn anti-AML candidate, that has a favorable set of structural, ADME and toxicological properties. A broad composition of matter patent application was filed in 2013. OT-82 is an NAMPT (NicotinAMide Phosphoribosyl Transferase) inhibitor. A remarkably broad spectrum of NAMPT functions positions OT-82 as a drug candidate for treatment of other NAMPT-dependent cancers, inflammatory diseases and disorders associated with deregulated circadian clock.

Screen Shot 2021-01-25 at 10_32_11 AM_pn

OncoXome is an oncology startup leading the path of cell communication therapy for patients with advanced cancer. We focus on gene editing therapy through systemic delivery by off-the shelf heterologous cancer exosomes. The approach is based on the concepts of oncogene addiction and cancer cell communication. We target KRAS mutations in advanced pancreatic, colorectal and lung cancers as our first step. OncoXome is at the preclinical stage and has proven its concept in vitro (achieving over 90% of cancer cell death with one single exposure in different cell lines - no genomic alterations, no cytotoxic mechanisms).


Ovensa Inc. is a preclinical stage biotech company advancing its siRNA lead candidate silencing galectin-1 (Gal-1) overexpression in the tumor microenvironment to improve therapeutic outcomes of immuno-oncology checkpoint inhibitors as a combination therapy in head & neck cancer. Gal-1 is a glycan-binding protein playing major roles in cancer by modulating different processes leading to metastasis, recurrence, enhanced cancer stem cell properties, resistance towards treatments (e.g. immunotherapy, chemotherapy, radiotherapy), and bad tumor prognosis. Ovensa is now raising $15M USD to advance the development of its lead candidate program TRIOZAN™/siRNA Gal-1 nanotherapeutic toward the completion of a first-in-human/proof-of-concept clinical study.


We are an R&D based biotech company focusing on the development of antibody therapeutics to treat neovascular disorders, tumors, and ocular diseases. We are looking for a partnership to co-develop or license out our preclinical and clinical assets.


pHLIP, Inc is a clinical-stage biopharmaceutical company dedicated to improving patient health by using our peptide-based targeted delivery platform to treat cancer and other acidic tissue diseases. pHLIP, Inc. was founded to bring its proprietary pHLIP® (pH-Low Insertion Peptide) Platform Technology to the clinic, improving the treatment of diseases where visualization and/or targeted therapy would be highly advantageous. pHLIP® peptides target metabolically active (glycolytic and acidic) cells in diseased tissues, where they insert directionally across the cell membrane. Therapeutic or imaging molecules can be anchored to the surfaces of acidic diseased cells or translocated and released directly into acidic diseased cells by pHLIP® peptides. The technology has been licensed from Yale, the University of Rhode Island, and the Memorial Sloan Kettering Cancer Center, and the licenses include exclusive Worldwide commercial rights to the extensive pH peptide patent families and pHLIP® trademark. For more information, visit

PinotBio, Inc. (“PinotBio”) is a clinical stage biotech focusing on the development of innovative new drugs for the treatment of refractory/resistant cancers. PinotBio was founded in 2017 and is developing 2 phase 1 stage candidates (NTX-301, oral targeted anticancer agents for both hematological and solid malignancies, and NTX-101, topical glaucoma treatment) along with a preclinical ADC platform. NTX-301 is an orally available Best-in-class DNMT1 inhibitor primarily targeting elderly AML. NTX-301’s unique property, high potency/excellent safety profile/ease of administration, and the potential for indication expansion to the area of high unmet medical needs (Pt resistant solid tumors, Adult recurrent T-cell ALL), makes NTX-301 as an attractive clinical stage candidate.


Pleco Therapeutics BV is a Dutch private limited company developing new medicines to improve the survival rate of cancer patients. Pleco develops breakthrough therapy that addresses metal toxicity and that cleans up the tumour microenvironment to boost the effect of chemotherapy. The first therapies are being developed for AML and SCLC and are now tested in preclinical models.

Promaxo is founded by a team of entrepreneurs and health care innovators to develop a minimally invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 60 patents, the Company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. The Company’s award-winning MR platform is 510k cleared and is ready for clinical launch in the US urology market.


PROMISS Diagnostics is a venture-stage biotech company that develops bio-analytical solutions to assist physicians in improving women’s health outcomes.  Its first-generation multi-analyte blood test (named PROMISS, for “Predicting Risk of Ovarian Malignancy in Serum Samples”) distinguishes malignant from benign ovarian masses.

Qrono Inc. develops patentable nanomedicines that reprogram antigen presenting cells in cancer and other diseases. Our platform aims for transformation through exquisite specificity that produces first-in-class drugs with new efficacies against validated targets. Lead compound, QR213 is a small molecule checkpoint inhibitor that sustains and strengthens the immune activation process, addressing a need for specific CD8+ T cells shared by 60% of cancer patients. It has demonstrated efficacy and safety in non-human primates and mice.


Qu Biologics is a Phase 2 clinical stage biotech company with a novel transformative immunotherapy platform, Site Specific Immunomodulators (SSIs). SSIs are uniquely positioned in oncology since, unlike single-target drugs, SSIs restore all the important cells and anti-cancer immune pathways in a targeted organ, including NK cells, M1 macrophages and activated adaptive immune cells, upregulation of the NKG2D pathway and down-regulation of multiple important check-point inhibitors in a manner aligned with the body’s natural anti-cancer mechanisms. Qu has compelling clinical data from four completed Phase 2 studies with a very good safety profile in the more than 360 patients treated to date. With a very good safety profile, synergy and broad applicability across a wide range of cancers, Qu is seeking VC funding and Pharma partnership to accelerate the development of Qu's first-in-class SSI platform in oncology.


Rafael Pharmaceuticals is a pioneering, clinical-late stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers in both solid and hem malignancies by applying our deep understanding of the unique bio-energetic processes specific to cancer.


Relevant Biosciences mines the human B cell repertoire with our proprietary screening platform to discover and develop relevant natural human therapeutic antibodies for cancer with 5 antibodies in preclinical testing.


RubrYc is a preclinical precision oncology company that uses a proprietary engineering approach to discover novel cancer medicines. The Company’s platform leverages machine learning to discover a novel class of antigens which are used to steer antibody discovery to prescribed epitopes. Our most advanced project has demonstrated in vivo efficacy in multiple models and we are about to begin IND-enabling activities. The Company expects to announce its first co-discovery partnership this quarter and we are raising Series B later this year to go to clinic.


Saccharo has discovered a game changing cancer immune shielding pathway based on a novel polysaccharide target found uniquely on cancer cells only. Expression of the polysaccharide target depends on re-expression of a fetal gene. Antibody to this polysaccharide target directly kill cancer cells and reduces tumors to scar tissues in preliminary mouse studies.


SciTech is a clinical stage, specialty pharmaceutical company that has developed a patented, nanoparticle delivery platform, SDP, to maximize the bioavailability of water-insoluble therapeutics, while maintaining or improving safety profiles. SciTech’s lead drug candidate is ST-001, a nano-particle formulation that enables the safe, rapid, intravenous (IV) delivery of high-dose fenretinide. In thousands of patients and multiple clinical trials, fenretinide has been shown to be a safe and effective anticancer therapeutic*, with evidence of multiple Mechanisms of Action for greater clinical outcomes. SciTech believes that ST-001 will become a first-line, highly effective, widely-used, and affordable anti-cancer therapeutic agent to improve the lives of cancer patients worldwide.

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 related products. Seneca Therapeutics is also developing armed versions of SVV-001 to selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.


Headquartered in British Columbia, Canada, SignalChem was established in 2004 and became a global leader in cell signaling and protein engineering. The company employs 60 scientists and consists of four business units. SignalChem’s Bioreagent unit generates worldwide, annual sales expected to reach ~$8M this year. This unit’s success has enabled the Drug Discovery unit to remain non-diluted and self-funded. The Drug Discovery unit includes five projects in various stages of development benefiting from the company’s core expertise and knowledge. SLC-391 (a potent and selective AXL inhibitor) is its most advanced program in late-Phase I clinical development. SignalChem is now entering its first-ever round of financing, seeking $20M to complete Phase II clinical development in oncology, which is planned to start in Q1, 2022. SignalChem is open to a variety of business/financial models to support our efforts to bring SLC-391 to patients suffering from Cancer. To learn more about SLC-391, join us for a partnering meeting or attend our conference presentation. We look forward to meeting you.


SIWA Therapeutics, Inc. has developed a proprietary humanized monoclonal antibody (“mAb”), 318H, that selectively targets a biomarker on cells exhibiting a combination of: (a) an abnormally high level of glycolysis (Warburg effect) and (b) oxidative stress. i.e. (1) cancer cells, (2) senescent cells, and (3) microbially-infected cells .


Summit Biomedical Imaging is a clinical stage cancer diagnostics company looking to transform the oral cancer detection market by bringing our first product, a fluorescent biomarker containing mouthwash for detecting oral cancer, to market by late 2023. Oral cancer detection is a $1B+ annual market in the U.S. At our anticipated price point for our target market segment, this is a $63M+ opportunity. We are looking to raise a seed round to complete our clinical development and continue our manufacturing development.


Tactical Therapeutics, Inc is a clinical stage private company in New York, NY, developing its patented small molecule, a first-in-class inhibitor of non-voltage dependent calcium signaling and multi-kinases, for the treatment of glioblastoma (GBM) and other solid cancers. Proof-of-concept was observed in Phase 1B in 42 GBM patients, with 62% overall survival at 24 months. CTO has the Orphan drug designation for malignant gliomas and is expected to be on the fast-track approval.


TAE Life Sciences (TLS) is privately-held biologically targeted radiation therapy company spun out from TAE Technologies in 2017 to create and commercialize a new cancer platform based on boron neutron capture therapy (BNCT). BNCT is a new type of radiation therapy that uses a high energy reaction of boron-10 and thermal neutrons, which individually have little effect on the human body. TLS is the only company developing both the target drugs and in-hospital neutron source required for this game-changing combination cancer therapy.

Telexos 300x.png

Telexos is a Cancer Diagnostics Startup and develops products for the Cancer Research and Cancer Diagnostics market. In addition, we also offer services (e.g., support of clinical studies or development of companion diagnostics for Pharma companies).


Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive is selling the CellAssist and the CellAssist 50. Both collect 1,000’s of images of live cells in culture, analyzes them, and builds a centralized database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells, generating large amounts of data for live cell biology. Users include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, the Broad Institute as well as large and small pharma/biotech companies.Thrive has raised $25M to-date, has 64 patent applications (of which 14 have issued), has an experienced management team and Board with many significant exits, and has 17 employees.

Tosk Inc. is a biopharmaceutical company dedicated to improving outcomes for cancer patients by developing new drugs to improve the safety and efficacy of existing therapies and to block the activity of cancer genes.  Side effects limit the use and effectiveness of many of today’s pharmaceutical products. Tosk employs proprietary methods to discover and develop new drugs that selectively block the adverse effects of existing treatments while maintaining their efficacy. Tosk’s drugs are not only designed to improve cancer treatment regimens, but since they are inexpensive, small molecules, will serve a worldwide market.  Tosk also recently developed a new technology to discover drugs that block activity of cancer genes. This technology is being deployed to discover drugs for indications that have previously been considered “undruggable.” Tosk’s first target for this technology is the mutant kRAS gene that drives as many as 30% of all cancers.


Tradewind BioScience, Inc., is dedicated to developing therapeutics for novel targets. Our most advanced candidate is a multifaceted attack antibody that can be used in multiple malignancies. It is validated in pre-clinical models of ovarian cancer as able to both potently attack primary and metastatic cancer and to enable anti-tumor immunity to boost and expand the effectiveness of checkpoint inhibitor therapy.


Travera has developed a new technology for identifying effective cancer drugs and drug combinations for cancer patients. Our approach uses a new measurement device invented at MIT that weighs single cells with sub-picogram accuracy, enabling us to directly measure the response of cancer cells to cancer drugs for each individual patient. Our unique diagnostic tests will enable oncologists to identify off-label drugs that extend their patient's lives, enable payers to avoid paying for ineffective drugs, and enable drug developers to select patients for clinical trials who will be responsive to their investigational drugs.


Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3. STAT3 is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that the company’s lead asset in cancer, TTI-101, is well tolerated and has clinical activity across a broad range of tumors including multiple durable responses.

Vivan Therapeutics (formerly My Personal Therapeutics) provides personalised cancer therapeutics utilising technology developed at and in partnership with Mt Sinai Medical Center. We identify personalised cancer treatments for patients based on their tumor genetics. For each patient, we build a genetically matched fruit fly model of the tumour, which is used for large-scale drug screening to find novel and effective drug combinations. This platform can treat even difficult cancers with combinations of approved drugs. Using our proprietary screening data, we are building a powerful AI-driven digital health tool, which can predict effective treatment options rapidly. Our in vivo, high throughput drug screening platform is also used to power biopharma discovery and development.


A medical device diagnostics & surgical tools company utilising bioelectric technology to differentiate tissue structure which is a surrogate for disease progression. Lead product already within the test-bed market in the UK’s NHS cervical cancer pathway. The higher efficacy is already helping hospitals better manage capacity. The diagnostic device provides results at the bedside which allows for better efficiency within the pathway. The company is now scaling to the USA and China markets. The core platform is being developed for other epithelial cancers and tissue margin assessment during surgery.